EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

2024 FDA TIDES (Peptides and Oligonucleotides) Harvest

Othman Al Musaimi iD, Danah AlShaer iD, Beatriz G de la Torre iD, Fernando Albericio iD

Pharmaceuticals · 20.02.2025 · 18 (3) · 291

DOI: 10.3390/ph18030291 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 20.02.2025. Verfasst von Othman Al Musaimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2024, the FDA approved fifty novel drugs, including four peptides and oligonucleotides (TIDEs) (two pepTIDEs and two oligonucleoTIDEs), highlighting their increasing importance as effective alternatives to traditional drug classes. TIDEs provide essential therapies for complex diseases, such as genetic disorders, rather than merely addressing symptoms. In addition to oligonucleotide therapeutics for various genetic conditions, peptides became the first approved treatment for Rett Syndrome in 2023 and were also used to treat Niemann–Pick disease type C (NPC) in 2024. Interestingly, among the strategies employed in recent approvals to enhance stability and/or delivery, the prodrug approach, exemplified by palopegteriparatide and pegulicianine, is emerging as a more targeted and precise therapeutic strategy. Additionally, the Enhanced Stabilization Chemistry (ESC)-GalNAc platform has been expanded for hepatic delivery of a new oligonucleotide drug, olezarsen. Furthermore, novel modifications to the ribose moiety in oligonucleotides, such as the 3′-amino substitution in imetelstat, enhance their stability. This review examines the TIDES approved in 2024 based on their chemical structure, medical targets, modes of action, administration routes, and common adverse effects. In addition, it highlights how the prodrug strategy has improved targeting efficiency and extended the half-lives of the active drugs.

Schlagwörter

Stichwörter der Autor:innen

FDA approvalsdrugsimetelstatlevacetylleucineoligonucleotidespalopegteriparatidepegulicianinepeptides

Autor:innen und Institutionen

  • School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
  • Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.
  • School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
  • School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
  • Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.

ORCID-Profile: Othman Al Musaimi, Danah AlShaer, Beatriz G de la Torre, Fernando Albericio

Zitieren

APA

Al Musaimi, O., AlShaer, D., de la Torre, B. G., & Albericio, F. (2025). 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 18(3), 291. https://doi.org/10.3390/ph18030291

Vancouver

Al Musaimi O, AlShaer D, de la Torre BG, Albericio F. 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2025;18(3):291. doi:10.3390/ph18030291

BibTeX
@article{AlMusaimi2025,
  author = {Al Musaimi, Othman and AlShaer, Danah and de la Torre, Beatriz G and Albericio, Fernando},
  title = {2024 FDA TIDES (Peptides and Oligonucleotides) Harvest},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {3},
  pages = {291},
  doi = {10.3390/ph18030291}
}
Kostenlos starten →